• Oncotelic: Chairman and CEO Trieu Vuong bought 240,000 common shares at USD 0.04 in an open-market purchase.
• Directly held stake rose to 94,124,319 shares.
• Also reports indirect holdings of 16,780,384 shares via Autotelic Inc. and 6,872,529 shares held by a spouse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031846), on July 02, 2026, and is solely responsible for the information contained therein.